Abstract: We shared a rare case with PD-L1 negative GC BrM responsive to PD-1/PD-L1 inhibitors, the mechanism of which is still unclear. The protocol of therapeutic choice for late-stage GC with BrM is urgently needed. And we are expecting biomarkers other than PD-L1 expressions to predict the efficacy of ICI treatment.
Introduction
Gastric cancer (GC) rarely metastasizes to the brain, but when it does, the prognosis is typically poor, with no established standard of care. While immune checkpoint inhibitors (ICIs) like PD-1/PD-L1 inhibitors have transformed late-stage GC treatment, their clinical application is usually guided by PD-L1 protein expression. This case report, published in Frontiers in Oncology, challenges this paradigm by detailing a patient with PD-L1 negative GC brain metastasis (BrM) who achieved a complete, durable remission.
Clinicians face two primary challenges in treating BrM with immunotherapy: the blood-brain barrier (BBB), which may limit drug delivery, and the reliability of biomarkers like PD-L1, which might exclude patients who could otherwise benefit. This study investigates whether patients currently classified as "negative" should be reconsidered for ICI therapy.
Methods
This clinical case report follows a 46-year-old male patient through a longitudinal treatment course. Diagnostic and monitoring methods included:
- Surgical Intervention: Multiple craniotomies for resection of metastatic lesions.
- Imaging: Disease progression and response monitoring via CT, MRI (T1-weighted with gadolinium), and PET-CT.
- Pathology & IHC: Standard Hematoxylin and Eosin (HE) staining and Immunohistochemistry (IHC) to determine tumor type and PD-L1 status (Combined Positive Score [CPS] and Tumor Proportion Score [TPS]).
- Multiplex Immunofluorescence (mIHC/IF): Used to map specific immune cells (CD4, CD8, CD20, and CD68) within the tumor microenvironment to assess immune infiltration beyond standard protein expression.
Key Insights
The study offers several critical insights into the success of ICI treatment in this "negative" biomarker case:
- The "Leaky" Blood-Tumor Barrier: The authors suggest that brain metastases disrupt the BBB, creating a more permeable "blood-tumor barrier" (BTB). This likely facilitated the accumulation of pembrolizumab within the brain lesions.
- Beyond PD-L1 Expression: Although the tumor was PD-L1 negative (CPS < 1), multiplex imaging revealed a "hot" tumor microenvironment dense with CD8+ T lymphocytes and CD68+ macrophages. This suggests that immune cell infiltration may be a more robust predictor of ICI efficacy than PD-L1 expression alone.
- Spatial Heterogeneity: PD-L1 expression can vary significantly between primary tumors and metastases. Relying on a single biopsy site may lead to suboptimal treatment decisions.
- Chemo-Immunotherapy Synergy: The patient received capecitabine alongside pembrolizumab. The chemotherapy may have helped "reengineer" the tumor immunity, creating a synergistic effect that triggered the complete response.
Key Results
The patient's response to the combination of pembrolizumab and capecitabine was both rapid and exceptionally durable, as evidenced by longitudinal imaging.
- Rapid Tumor Shrinkage: After just one 4-week cycle of treatment, the brain tumor volume decreased by nearly 80%.
- Complete Response (CR): Within eight weeks of starting immunotherapy, the patient achieved a complete response, with no detectable tumor on imaging.
- Long-term Survival: The remission has proven remarkably durable; the patient remains cancer-free after more than 4 years (1252 days) of follow-up.
- Biomarker Paradox: These results were achieved despite a Combined Positive Score (CPS) and Tumor Cell Proportion Score (TPS) of less than 1%, highlighting the potential for false negatives in current screening protocols.
Conclusion
While this case represents an "exceptional responder" (N=1), it highlights the limitations of current biomarkers. The authors emphasize the urgent need for new predictive metrics, such as tumor mutational burden (TMB) or immune cell infiltration density, and the development of standardized therapeutic protocols for gastric cancer patients with brain metastases.
Summary updated